Rosenthal S A, Haseman M K, Polascik T J
Division of Radiation Oncology, Radiological Associates of Sacramento Medical Group, Inc., California 95815, USA.
Tech Urol. 2001 Mar;7(1):27-37.
Capromab pendetide (ProstaScint) is an indium In 111 ((111)In)-labeled monoclonal antibody to prostate-specific membrane antigen (PSMA) used to image prostate cancer. The appropriate techniques for obtaining images with this modality and the appropriate clinical indications for this study are in the process of being optimized.
From 1994 to 2000, 631 monoclonal antibody imaging studies with (111)In capromab pendetide were performed. The accuracy and utility of this modality in the primary staging of patients with disease at high risk of metastasis and patients with recurrent or residual disease after primary therapy were evaluated.
In high-risk patients evaluated for risk of lymph node metastases prior to pelvic lymph node dissection, capromab pendetide imaging was found to have a positive predictive value (PPV) of 62%, negative predictive value (NPV) of 72%, sensitivity of 62%, and specificity of 72%. In patients evaluated with capromab pendetide imaging for prostatic fossa recurrence using prostatic fossa needle biopsy as the gold standard, capromab pendetide imaging was found to have a PPV of 50%, NPV of 70%, sensitivity of 49%, and specificity of 71%.
The sensitivity and NPV of (111)In capromab pendetide imaging are better than those of computed tomography and magnetic resonance imaging for detection of soft-tissue and nodal metastases from prostate cancer. The utility of this modality has been demonstrated in the primary staging of patients with disease at high risk of metastasis. Patients with recurrent or residual disease after primary therapy also may benefit from capromab pendetide imaging prior to selection of salvage therapy. Innovative methods for the use of capromab pendetide imaging in radiation therapy treatment planning are under development.
卡普单抗喷地肽（ProstaScint）是一种铟In 111（（111）In）标记的针对前列腺特异性膜抗原（PSMA）的单克隆抗体，用于前列腺癌成像。使用这种方式获取图像的合适技术以及本研究的合适临床指征正在优化过程中。
1994年至2000年，进行了631例用（111）In卡普单抗喷地肽的单克隆抗体成像研究。评估了这种方式在有高转移风险疾病患者的初始分期以及初始治疗后复发或残留疾病患者中的准确性和实用性。
在盆腔淋巴结清扫术前评估淋巴结转移风险的高危患者中，发现卡普单抗喷地肽成像的阳性预测值（PPV）为62%，阴性预测值（NPV）为72%，敏感性为62%，特异性为72%。在以前列腺窝针吸活检为金标准用卡普单抗喷地肽成像评估前列腺窝复发的患者中，发现卡普单抗喷地肽成像的PPV为50%，NPV为70%，敏感性为49%，特异性为71%。
（111）In卡普单抗喷地肽成像在检测前列腺癌软组织和淋巴结转移方面的敏感性和NPV优于计算机断层扫描和磁共振成像。这种方式的实用性已在有高转移风险疾病患者的初始分期中得到证实。初始治疗后复发或残留疾病的患者在选择挽救治疗前也可能从卡普单抗喷地肽成像中获益。卡普单抗喷地肽成像在放射治疗治疗计划中的创新使用方法正在研发中。
